143 related articles for article (PubMed ID: 23849748)
1. Reduced clopidogrel metabolism in a multiethnic population: prevalence and rates of recurrent cerebrovascular events.
Spokoyny I; Barazangi N; Jaramillo V; Rose J; Chen C; Wong C; Tong D
J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):694-8. PubMed ID: 23849748
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease.
Lee JB; Lee KA; Lee KY
Yonsei Med J; 2011 Sep; 52(5):734-8. PubMed ID: 21786436
[TBL] [Abstract][Full Text] [Related]
3. Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
Zhang J; Zhang J; Sun H; Ming T; Liu X; Cong Y; Li F; Li Z
Int J Clin Pharmacol Ther; 2017 Oct; 55(10):789-797. PubMed ID: 28766499
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel and genetic testing: is it necessary for everyone?
Goswami S; Cheng-Lai A; Nawarskas J
Cardiol Rev; 2012; 20(2):96-100. PubMed ID: 22293861
[TBL] [Abstract][Full Text] [Related]
5. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
McDonough CW; McClure LA; Mitchell BD; Gong Y; Horenstein RB; Lewis JP; Field TS; Talbert RL; Benavente OR; Johnson JA; Shuldiner AR
J Am Heart Assoc; 2015 May; 4(6):e001652. PubMed ID: 26019129
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of clopidogrel: evidence and perspectives.
Yin T; Miyata T
Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
Jang JS; Cho KI; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Seol SH; Kim DI; Kim BH; Park YH; Je HG; Jeong YH; Lee SW
Am J Cardiol; 2012 Aug; 110(4):502-8. PubMed ID: 22591668
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
Kim HS; Chang K; Koh YS; Park MW; Choi YS; Park CS; Oh M; Kim EY; Shon JH; Shin JG; Seung KB
Circ Cardiovasc Genet; 2013 Oct; 6(5):514-21. PubMed ID: 24019397
[TBL] [Abstract][Full Text] [Related]
9. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
[TBL] [Abstract][Full Text] [Related]
10. CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.
Jeong TD; Kim SM; Kim HJ; Lee W; Kwon SU; Min WK; Kang DW; Chun S
J Stroke Cerebrovasc Dis; 2015 Feb; 24(2):440-6. PubMed ID: 25529343
[TBL] [Abstract][Full Text] [Related]
11. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations.
Angiolillo DJ; Ueno M
JACC Cardiovasc Interv; 2011 Apr; 4(4):411-4. PubMed ID: 21511220
[No Abstract] [Full Text] [Related]
12. Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Pan Y; Chen W; Xu Y; Yi X; Han Y; Yang Q; Li X; Huang L; Johnston SC; Zhao X; Liu L; Zhang Q; Wang G; Wang Y; Wang Y
Circulation; 2017 Jan; 135(1):21-33. PubMed ID: 27806998
[TBL] [Abstract][Full Text] [Related]
13. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.
Kim KA; Park PW; Hong SJ; Park JY
Clin Pharmacol Ther; 2008 Aug; 84(2):236-42. PubMed ID: 18323861
[TBL] [Abstract][Full Text] [Related]
14. Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With
Lin Y; Wang A; Li J; Lin J; Wang D; Meng X; Ou L; Chen W; Zhao X; Liu L; Wang Y; Wang Y;
Stroke; 2017 Apr; 48(4):998-1004. PubMed ID: 28289237
[TBL] [Abstract][Full Text] [Related]
15. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
[TBL] [Abstract][Full Text] [Related]
16. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
Tiroch KA; Sibbing D; Koch W; Roosen-Runge T; Mehilli J; Schömig A; Kastrati A
Am Heart J; 2010 Sep; 160(3):506-12. PubMed ID: 20826260
[TBL] [Abstract][Full Text] [Related]
18. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
[TBL] [Abstract][Full Text] [Related]
20. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
